Hi Marie,
Here is an abstract from ASH about Nplate (Romiplostim) in MDS patients:
http://ash.confex.com/ash/2010/webpr...aper33611.html
"Peripheral blasts were increased in 2 pts (MDS-U and RA at baseline) and resolved in both cases after discontinuation of romiplostim. Three cases of progression to AML were reported, corresponding to an annual on-study event rate of 5.9% (95% CI: 1.9% to 18.3%). These pts were IPSS-risk low or int-1 at baseline and had a WHO classification of RAEB-1 or RCMD. During this study, they received 750 mcg romiplostim for 6, 49, and 36 weeks. Bone marrow blasts were 39%, 65%, and 40% at AML diagnosis."
They don't report anything about increased bone marrow fibrosis that is an expected adverse reaction.
Kind regards
Birgitta-A